Suchergebnisse - "Sacco, Michael Dominic"

PubPharm (13)

1

Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and FlipGFP-based reporter assay

enthalten in: bioRxiv.org | 2023

von Xia, Z. | Sacco, M. | Ma, C. | +12

2

Development of the Safe and Broad-Spectrum Aldehyde and Ketoamide Mpro inhibitors Derived from the Constrained α, γ-AA Peptide Scaffold

enthalten in: Chemistry (Weinheim an der Bergstrasse, Germany) | 2023

von Wang, L. | Ma, C. | Sacco, M. | +6

3

Development of the Safe and Broad‐Spectrum Aldehyde and Ketoamide Mpro inhibitors Derived from the Constrained α, γ‐AA Peptide Scaffold

enthalten in: Chemistry – A European Journal | 2023

von Wang, L. | Ma, C. | Sacco, M. | +6

4

The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition

enthalten in: Cell research | 2022

von Sacco, M. | Hu, Y. | Gongora, M. | +5

5

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

enthalten in: Journal of medicinal chemistry | 2022

von Kitamura, N. | Sacco, M. | Ma, C. | +14

6

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity

enthalten in: Journal of the American Chemical Society | 2021

von Ma, C. | Xia, Z. | Sacco, M. | +13

7

Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay

enthalten in: ACS central science | 2021

von Ma, C. | Sacco, M. | Xia, Z. | +14

UpdateOf: bioRxiv. 2021 Mar 16;:. - PMID 33758866

8

Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and FlipGFP-based reporter assay

enthalten in: bioRxiv : the preprint server for biology | 2021

von Xia, Z. | Sacco, M. | Ma, C. | +12

UpdateIn: ACS Cent Sci. 2021 Jul 28;7(7):1245-1260. - PMID 34341772

9

An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity

enthalten in: bioRxiv.org | 2020

von Kitamura, N. | Sacco, M. | Ma, C. | +12

10

Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L

enthalten in: bioRxiv.org | 2020

von Sacco, M. | Ma, C. | Lagarias, P. | +14